The FDA in June began to mandate that unapproved legacy drugs, such as quinine, must undergo the same approval process that new drugs go through as part of the agency's new strategy to improve drug safety. These types of longstanding drugs could be withdrawn for the market unless they submit to the FDA's expensive new drug application process, leading The Wall Street Journal to call for the FDA to give them a "special regulatory pathway" for approval.

Related Summaries